GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Shiller PE Ratio

CORT (Corcept Therapeutics) Shiller PE Ratio : 80.73 (As of Apr. 12, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Shiller PE Ratio?

As of today (2025-04-12), Corcept Therapeutics's current share price is $68.62. Corcept Therapeutics's E10 for the quarter that ended in Dec. 2024 was $0.85. Corcept Therapeutics's Shiller PE Ratio for today is 80.73.

The historical rank and industry rank for Corcept Therapeutics's Shiller PE Ratio or its related term are showing as below:

CORT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 32.11   Med: 65.12   Max: 679.5
Current: 81.08

During the past years, Corcept Therapeutics's highest Shiller PE Ratio was 679.50. The lowest was 32.11. And the median was 65.12.

CORT's Shiller PE Ratio is ranked worse than
83.67% of 147 companies
in the Biotechnology industry
Industry Median: 32.38 vs CORT: 81.08

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Corcept Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was $0.260. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.85 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Corcept Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Corcept Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Shiller PE Ratio Chart

Corcept Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 162.88 62.68 42.18 49.41 59.54

Corcept Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.41 35.28 42.72 56.90 59.54

Competitive Comparison of Corcept Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Corcept Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Shiller PE Ratio falls into.


;
;

Corcept Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Corcept Therapeutics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=68.62/0.85
=80.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Corcept Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.26/133.1571*133.1571
=0.260

Current CPI (Dec. 2024) = 133.1571.

Corcept Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.050 99.621 -0.067
201506 -0.020 100.684 -0.026
201509 -0.010 100.392 -0.013
201512 0.010 99.792 0.013
201603 0.000 100.470 0.000
201606 0.010 101.688 0.013
201609 0.020 101.861 0.026
201612 0.040 101.863 0.052
201703 0.040 102.862 0.052
201706 0.100 103.349 0.129
201709 0.110 104.136 0.141
201712 0.770 104.011 0.986
201803 0.140 105.290 0.177
201806 0.140 106.317 0.175
201809 0.140 106.507 0.175
201812 0.180 105.998 0.226
201903 0.150 107.251 0.186
201906 0.170 108.070 0.209
201909 0.220 108.329 0.270
201912 0.240 108.420 0.295
202003 0.250 108.902 0.306
202006 0.230 108.767 0.282
202009 0.170 109.815 0.206
202012 0.200 109.897 0.242
202103 0.180 111.754 0.214
202106 0.210 114.631 0.244
202109 0.240 115.734 0.276
202112 0.260 117.630 0.294
202203 0.200 121.301 0.220
202206 0.240 125.017 0.256
202209 0.300 125.227 0.319
202212 0.140 125.222 0.149
202303 0.140 127.348 0.146
202306 0.250 128.729 0.259
202309 0.280 129.860 0.287
202312 0.280 129.419 0.288
202403 0.250 131.776 0.253
202406 0.320 132.554 0.321
202409 0.410 133.029 0.410
202412 0.260 133.157 0.260

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corcept Therapeutics  (NAS:CORT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Corcept Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics Business Description

Traded in Other Exchanges
Address
101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Executives
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025